MDGL Madrigal Pharmaceuticals Inc
Price (delayed)
$334.6
Market cap
$7.39B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$21.9
Enterprise value
$7.4B
Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone pathway in the liver, which is a key regulatory mechanism common to a spectrum
Highlights
The company's gross profit has surged by 135% QoQ
The revenue has surged by 135% since the previous quarter
The equity has soared by 86% year-on-year but it is down by 2.9% since the previous quarter
The company's net income fell by 25% YoY but it rose by 10% QoQ
The debt has grown by 2% year-on-year
Key stats
What are the main financial stats of MDGL
Market
Valuations
Earnings
Shares outstanding
22.08M
Market cap
$7.39B
Enterprise value
$7.4B
Price to earnings (P/E)
N/A
Price to book (P/B)
9.67
Price to sales (P/S)
39.51
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
41.1
Revenue
$180.13M
Gross profit
$173.9M
Operating income
-$497.88M
Net income
-$465.89M
EBIT
-$451.22M
EBITDA
-$450.53M
Free cash flow
-$462.03M
Per share
Balance sheet
Liquidity
EPS
-$21.9
EPS diluted
-$21.9
Free cash flow per share
-$21.72
Book value per share
$34.59
Revenue per share
$8.47
TBVPS
$48.77
Total assets
$1.04B
Total liabilities
$287.86M
Debt
$119.57M
Equity
$754.38M
Working capital
$863.65M
Debt to equity
0.16
Current ratio
6.1
Quick ratio
5.82
Net debt/EBITDA
-0.03
Margins
Efficiency
Dividend
EBITDA margin
-250.1%
Gross margin
96.5%
Net margin
-258.6%
Operating margin
-276.4%
Return on assets
-43.4%
Return on equity
-57.5%
Return on invested capital
-66.8%
Return on capital employed
-51.7%
Return on sales
-250.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MDGL stock price
How has the Madrigal Pharmaceuticals stock price performed over time
Intraday
3.28%
1 week
0.23%
1 month
-1.95%
1 year
36.85%
YTD
8.44%
QTD
1.02%
Financial performance
How have Madrigal Pharmaceuticals's revenue and profit performed over time
Revenue
$180.13M
Gross profit
$173.9M
Operating income
-$497.88M
Net income
-$465.89M
Gross margin
96.5%
Net margin
-258.6%
The company's gross profit has surged by 135% QoQ
The revenue has surged by 135% since the previous quarter
The net margin has surged by 62% since the previous quarter
Madrigal Pharmaceuticals's operating margin has soared by 61% from the previous quarter
Growth
What is Madrigal Pharmaceuticals's growth rate over time
Valuation
What is Madrigal Pharmaceuticals stock price valuation
P/E
N/A
P/B
9.67
P/S
39.51
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
41.1
The EPS has increased by 13% from the previous quarter but it has decreased by 10% YoY
The equity has soared by 86% year-on-year but it is down by 2.9% since the previous quarter
The stock's price to book (P/B) is 59% less than its 5-year quarterly average of 22.7 but 34% more than its last 4 quarters average of 7.0
The revenue has surged by 135% since the previous quarter
Efficiency
How efficient is Madrigal Pharmaceuticals business performance
The ROE has soared by 74% YoY and by 20% from the previous quarter
The ROS has soared by 62% from the previous quarter
MDGL's return on assets has surged by 56% year-on-year and by 19% since the previous quarter
Madrigal Pharmaceuticals's ROIC has increased by 46% YoY and by 22% from the previous quarter
Dividends
What is MDGL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MDGL.
Financial health
How did Madrigal Pharmaceuticals financials performed over time
Madrigal Pharmaceuticals's total assets has soared by 63% YoY but it has decreased by 2.9% from the previous quarter
Madrigal Pharmaceuticals's total liabilities has increased by 22% YoY but it has decreased by 2.8% from the previous quarter
The debt is 84% smaller than the equity
The equity has soared by 86% year-on-year but it is down by 2.9% since the previous quarter
Madrigal Pharmaceuticals's debt to equity has decreased by 45% YoY but it has increased by 7% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.